This paper assesses the consequences of residential instability during the first five years of a child’s life for a host of school readiness outcomes. Using data from the Fragile Families and Child Wellbeing Study, we examine the relationship between multiple moves and children’s cognitive...

Using the Fragile Families and Child Well-Being Study, this paper investigates how income volatility and union stability and transitions influence patterns in Food Stamp Program (FSP) participation among a sample of young families (n=1263). Multinomial logistic regression models suggest that...

Using the Fragile Families and Child Well-Being Study, this paper investigates how income volatility and union stability and transitions influence patterns in Food Stamp Program (FSP) participation among a sample of young families (n=1263). Multinomial logistic regression models suggest that...

A robust body of literature spanning several countries indicates a positive association between maternal employment and child body mass index (BMI). Fewer studies have examined the role of paternal employment. More importantly, little empirical work examines the mechanisms that might explain the...

The purpose of this research is to illustrate: i) the principles of what assessments are required when considering the need for additional evidence and the priority of proposed research; and ii) how these assessments might be informed by quantitative analysis based on standard methods of...

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial...

Following a licence extension to include those aged 6–11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...

Following a licence extension to include those aged 6-11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...